Molecular determinants of positive allosteric modulation of the human metabotropic glutamate receptor 2

British Journal of Pharmacology

Volumn 172, Issue 9, 2015, Pages 2383-2396

  Farinha, A ^a   Lavreysen, H ^a   Peeters, L ^a   Russo, B ^a   Masure, S ^a   Trabanco, A A ^a   Cid, J ^a   Tresadern, G ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID RECEPTOR AFFECTING AGENT; GLUTAMIC ACID; LIGAND; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; PROTEIN BINDING;

ANIMAL; BINDING COMPETITION; BINDING SITE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MOLECULAR DOCKING; MUTATION; PROTEIN CONFORMATION; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CHO CELLS; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; EXCITATORY AMINO ACID AGENTS; GLUTAMIC ACID; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; MUTAGENESIS, SITE-DIRECTED; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 84926638187     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13065     Document Type: Article

References (54)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Bonnefous C, Vernier J-M, Hutchinson JH, Gardner MF, Cramer M, James JK, et al. (2005). Biphenyl-indanones: allosteric potentiators of the metabotropic glutamate subtype 2 receptor. Bioorg Med Chem Lett 15: 4354-4358.
3. Bruno A, Guadix AE, Costantino G, (2009). Molecular dynamics simulation of the heterodimeric mGluR2/5HT2A complex. An atomistic resolution study of a potential new target in psychiatric conditions. J Chem Inf Model 49: 1602-1616.
4. Chiechio S, Nicoletti F, (2012). Metabotropic glutamate receptors and the control of chronic pain. Curr Opin Pharmacol 12: 28-34.
5. Cid JM, Duvey G, Cluzeau P, Nhem V, Macary K, Raux A, et al. (2010). Discovery of 1,5-disubstituted pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor. ACS Chem Neurosci 1: 788-795.
6. Cid JM, Duvey G, Tresadern G, Nhem V, Funary R, Cluzeau P, et al. (2012a). Discovery of 1,4-disubstituted 3-cyano-2-pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor. J Med Chem 55: 2388-2405.
7. Cid JM, Tresadern G, Vega JA, de Lucas AI, Matesanz E, Iturrino L, et al. (2012b). Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. J Med Chem 55: 8770-8789.
8. Cid-Nuñez JM, Trabanco-Suárez AA, MacDonald GJ, Duvey GAJ, Luetjens RJ, (2008a). Preparation of 3-cyano-4-(4-phenylpiperidin-1-yl)-pyridin-2-one derivatives for treating and preventing neurol. and psychiatric diseases associated with glutamate dysfunction. PCT Int. Appln. WO 2008/107479 A1.
9. Cid-Nuñez JM, Trabanco-Suárez AA, MacDonald GJ, Duvey GAJ, Lutjens RJ, (2008b). 1,4-Disubstituted 3-cyano-pyridone derivatives and their use as positive mgluR2-receptor modulators. PCT Int. Appln. WO 2008/107480 A1.
10. Cid-Nuñez JM, Oehlrich D, Trabanco-Suárez AA, Tresadern GJ, Vega Ramiro JA, Macdonald GJ, (2010a). Preparation of 1,2,3-triazolo[4,3-a]pyridine for the treatment or prevention of neurological and psychiatric disorders. PCT Int. Appln. WO 2010/130424 A1.
11. Cid-Nuñez JM, Trabanco-Suárez AA, Macdonald GJ, (2010b). Preparation of indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors for treating neurological and psychiatric disorders. PCT Int. Appln. WO 2010/060589 A1.
12. Conn PJ, Pin JP, (1997). Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37: 205-237.
13. Dore AS, Okrasa K, Patel JC, Serrano-Vega M, Bennett K, Cooke RM, et al. (2014). Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature 511: 557-562.
14. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD, (2008). Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33: 1603-1610.
15. Fell MJ, Witkin JM, Falcone JF, Katner JS, Perry KW, Hart J, et al. (2011). N-(4-( (2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. J Pharmacol Exp Ther 336: 165-177.
16. Galici R, Echemendia NG, Rodriguez AL, Conn PJ, (2005). A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 315: 1181-1187.
17. Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, et al. (2006). Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 318: 173-185.
18. Ghose S, Gleason KA, Potts BW, Lewis-Amezcua K, Tamminga CA, (2009). Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? Am J Psychiatry 166: 812-820.
19. Gregory KJ, Noetzel MJ, Rook JM, Vinson PN, Stauffer SR, Rodriguez AL, et al. (2012). Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships. Mol Pharmacol 82: 860-875.
20. 5) positive allosteric modulator (PAM) binding pocket: discovery of point mutations that engender a 'molecular switch' in PAM pharmacology. Mol Pharmacol 83: 991-1006.
21. Gregory KJ, Nguyen ED, Malosh C, Mendenhall JL, Zic JZ, Bates BS, et al. (2014). Identification of specific ligand-receptor interactions that govern binding and cooperativity of diverse modulators to a common metabotropic glutamate receptor 5 allosteric site. ACS Chem Neurosci 5: 282-295.
22. Gu G, Lorrain DS, Wei H, Cole RL, Zhang X, Daggett LP, et al. (2008). Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: implication in emotional responses and central disinhibition. Brain Res 1197: 47-62.
23. Hemstapat K, de Paulis T, Chen Y, Brady AE, Grover VK, Alagille D, et al. (2006). A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. Mol Pharmacol 70: 616-626.
24. Hemstapat K, Da Costa H, Nong Y, Brady AE, Luo Q, Niswender CM, et al. (2007). A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J Pharmacol Exp Ther 322: 254-264.
25. Huang S, Cao J, Jiang M, Labesse G, Liu J, Pin J-P, et al. (2011). Interdomain movements in metabotropic glutamate receptor activation. Proc Natl Acad Sci U S A 108: 15480-15485.
26. Imogai HJ, Cid-Nuñez JM, Duvey GAJ, Bolea CM, Nhem V, Finn TP, et al. (2006). Novel pyridinone derivatives and their use as positive allosteric modulators of mgluR2-receptors. PCT Int. Appln. WO 2006/030032 A1.
27. Imogai HJ, Cid-Nuñez JM, Andrés-Gil JI, Trabanco-Suárez AA, Oyarzábal-Santamarina J, Dautzenberg FM, et al. (2007). 1,4-Disubstituted 3-cyano-pyridone derivatives and their use as positive mgluR2-receptor modulators. PCT Int. Appln. WO 2007/104783 A2.
28. Johnson MP, Baez M, Jagdmann GE Jr, Britton TC, Large TH, Callagaro DO, et al. (2003). Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J Med Chem 46: 3189-3192.
29. Knoflach F, Mutel V, Jolidon S, Kew JNC, Malherbe P, Vieira E, et al. (2001). Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci U S A 98: 13402-13407.
30. 3H]JNJ-40068782. J Pharmacol Exp Ther 346: 514-527.
31. Leach K, Sexton PM, Christopoulos A, (2007). Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28: 382-389.
32. Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, et al. (1999). CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol 55: 453-461.
33. Lundström L, Bissantz C, Beck J, Wettstein JG, Woltering TJ, Wichmann J, et al. (2011). Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators. Br J Pharmacol 164: 521-537.
34. Malherbe P, Kratochwil N, Zenner MT, Piussi J, Diener C, Kratzeisen C, et al. (2003). Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-Methyl-6-(phenylethynyl)-pyridine. Mol Pharmacol 64: 823-832.
35. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, et al. (1997). Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic roperties. J Med Chem 40: 528-537.
36. Niswender CM, Conn JP, (2010). Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50: 295-322.
37. Pagano A, Ruegg D, Litschig S, Stoehr N, Stierlin C, Heinrich M, et al. (2000). The non-competitive antagonists 2-methyl-6-(phenethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group 1 metabotropic glutamate receptors. J Biol Chem 275: 33750-33758.
38. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13: 1102-1107.
39. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res 42 (Database Issue): D1098-D1106.
40. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, et al. (2011a). Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 469: 175-180.
41. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, et al. (2011b). Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477: 549-555.
42. Rowe BA, Schaffhauser H, Morales S, Lubbers LS, Bonnefous C, Kamenecka TM, et al. (2008). Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3 positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2 positive allosteric modulation site. J Pharmacol Exp Ther 326: 240-251.
43. Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, Jachec C, et al. (2003). Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol Pharmacol 64: 798-810.
44. Shigeyuki C, Hirohiko H, (2011). Targeting of metabotropic glutamate receptors for the treatment of schizophrenia. Curr Pharm Des 17: 94-102.
45. Trabanco AA, Cid JM, Lavreysen H, Macdonald GJ, Tresadern G, (2011a). Progress in the development of positive allosteric modulators of the metabotropic glutamate receptor 2. Curr Med Chem 18: 47-68.
46. Trabanco AA, Duvey G, Cid JM, Macdonald GJ, Cluzeau P, Nhem V, et al. (2011b). New positive allosteric modulators of the metabotropic glutamate receptor 2 (mGluR2): identification and synthesis of N-propyl-8-chloro-6-substituted isoquinolones. Bioorg Med Chem Lett 21: 971-976.
47. Trabanco AA, Duvey G, Cid JM, Macdonald GJ, Cluzeau P, Nhem V, et al. (2011c). New positive allosteric modulators of the metabotropic glutamate receptor 2 (mGluR2): identification and synthesis of N-propyl-5-substituted isoquinolones. MedChemComm 2: 132-139.
48. Trabanco AA, Tresadern G, Macdonald GJ, Vega JA, de Lucas AI, Matesanz E, et al. (2012). Imidazo[1,2-a]pyridines: orally active positive allosteric modulators of the metabotropic glutamate 2 receptor. J Med Chem 55: 2688-2701.
49. Trabanco AA, Cid JM, (2013). mGluR2 positive allosteric modulators: a patent review (2009-present). Expert Opin Ther Pat 23: 629-647.
50. Trabanco-Suárez AA, Tresadern GJ, Vega Ramiro JÁ, Cid-Nuñez JM, (2009). Preparation of imidazopyridine derivatives for use as mGluR2 receptor modulators. PCT Int. Appln. WO 2009/062676 A2.
51. Tresadern G, Cid JM, Macdonald GJ, Vega JA, de Lucas AI, García A, et al. (2010). Scaffold hopping from pyridones to imidazo[1,2-a]pyridines. New positive allosteric modulators of metabotropic glutamate 2 receptor. Bioorg Med Chem Lett 20: 175-179.
52. Tresadern G, Cid JM, Trabanco AA, (2014). QSAR design of triazolopyridine mGlu2 receptor positive allosteric modulators. J Mol Graph Model 53: 82-91.
53. Vinson PN, Conn PJ, (2012). Metabotropic glutamate receptors as therapeutic targets for schizophrenia. Neuropharmacology 62: 1461-1472.
54. Wu H, Wang C, Gregory KJ, Han GW, Cho HP, Xia Y, et al. (2014). Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science 344: 58-64.